Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.
23hon MSN
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...
Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...
The shares of pharmaceutical giant Eli Lilly (LLY) are falling 5% today after the company ... versus the mean estimate of ...
Eli Lilly has asked the U.S. government to pause price negotiations for prescription drugs, Bloomberg News reported on Monday ...
Stubbornly high readings on inflation and a run of better-than-expected readings on the U.S. economy have sent Wall Street ...
That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results,” said Eli Lilly Chair and CEO David A. Ricks. “We continued to make progress on our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback